Pre-earnings brief
Reports
Mon, Nov 16, 2026
Est. EPS
—
Est. revenue
—
Implied move
±13.5%
EPS beat rate
88%
CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products to prevent and treat serious medical conditions. With a market cap of $1 billion, it operates in the healthcare sector, which is increasingly important as the demand for effective medical treatments continues to grow.
Last quarter
In Q2 2026, CorMedix reported an EPS of $0.29, exceeding expectations by 11.54%, which led to a positive stock reaction of 14.65% the following day. However, revenue figures were not disclosed, leaving some uncertainty.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+38.23%
Avg 1-day reaction
-3.67%
Investors are anticipating another strong performance from CorMedix, especially after recent earnings surprises. However, the lack of guidance may lead to cautious sentiment.
Bull case
If CorMedix continues its trend of beating EPS estimates, it could signal strong operational performance and lead to increased investor confidence.
Bear case
Conversely, if the company fails to meet expectations or provide clear guidance, it may trigger a negative reaction in the stock price.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
Given the company's history of beating EPS estimates, this figure will be critical in shaping investor sentiment.
Q2
Will CorMedix provide any revenue guidance for the upcoming quarters?
Clear revenue guidance can help investors gauge the company's growth trajectory and market demand.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±6.1%
Why consensus could be wrong
The Street may be underestimating CorMedix's potential for continued earnings growth based on its recent performance and historical EPS surprises.
Supporting evidence
CorMedix has an 88% EPS beat rate over the last eight quarters, indicating strong operational execution.
The stock's recent positive reactions to earnings surprises suggest a trend that may not be fully reflected in current expectations.
Key risk
If the EPS comes in below $0.20, it could significantly undermine the bullish narrative.
Pre-commit to what would confirm each case.
The market is weighing the potential for continued earnings surprises against the uncertainty of revenue guidance.
Bull confirmed if
An EPS of $0.30 or higher would confirm the bull case and indicate strong operational performance.
Bear confirmed if
An EPS below $0.20 would confirm the bear case and raise concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±13.51%
Historical Avg
±15.2%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±13.5% while CRMD has averaged ±15.2% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.5%
30d HV
24.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.0%, with a raw directional average of -0.9% (modestly negative historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CorMedix beats expectations, history suggests the stock could see a modest uptick, reinforcing positive investor sentiment.
In line / cautious
If results are in line with expectations but lack guidance, the stock may experience volatility with a cautious outlook.
Miss
A miss could lead to a significant drop in stock price, as history indicates an average decline of around 11.52% following earnings misses.
The lines on the call that would change the story.